Denosumab biosimilar (GlycoNex)

地舒单抗生物类似药 (台湾糖联生技医药股份有限公司)

Report date: 2025/01/16 12:05:02

Base Information

Drug NameDenosumab biosimilar (GlycoNex)

Drug Alias NameSPD8 denosumab biosimilar (GlycoNex)SPD8SPD-8

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors

TargetsTumor necrosis factor ligand superfamily member 11

Therapy Area/IndicationsOsteoporosisNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwanJapan

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlyconex Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsOsteoporosisNeoplasms

Inactive IndicationsN/A

ATC CodeN/A